HC Wainwright reaffirmed their buy rating on shares of Nyxoah (NASDAQ:NYXH - Free Report) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.
Separately, Stifel Nicolaus cut their target price on shares of Nyxoah from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 14th.
View Our Latest Research Report on Nyxoah
Nyxoah Stock Up 2.3 %
Shares of NYXH traded up $0.14 during mid-day trading on Tuesday, reaching $6.15. The company had a trading volume of 291,345 shares, compared to its average volume of 62,178. The company has a market capitalization of $209.47 million, a price-to-earnings ratio of -3.29 and a beta of 1.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. Nyxoah has a 52 week low of $5.55 and a 52 week high of $12.21. The firm has a 50-day moving average price of $9.31 and a 200 day moving average price of $9.18.
Nyxoah (NASDAQ:NYXH - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. On average, sell-side analysts forecast that Nyxoah will post -1.91 EPS for the current year.
Institutional Investors Weigh In On Nyxoah
A number of large investors have recently modified their holdings of NYXH. Vestal Point Capital LP purchased a new position in Nyxoah in the 4th quarter worth $23,394,000. Ameriprise Financial Inc. purchased a new stake in shares of Nyxoah in the fourth quarter valued at approximately $135,000. Walleye Capital LLC raised its position in Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock worth $119,000 after acquiring an additional 2,862 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Nyxoah during the 4th quarter worth about $187,000. Finally, Geode Capital Management LLC lifted its position in shares of Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock valued at $137,000 after acquiring an additional 2,774 shares in the last quarter.
Nyxoah Company Profile
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Further Reading
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
